Based in Europe, a venture and growth capital firm provides expertise and funding to entrepreneurs and companies with global ambitions in life sciences and information technologies. The firm focuses on early to growth and expansion stage including spin-offs and restarts. The firm prefers to be the lead investor and possibly co-lead. The firm seeks to allocate €7-15 million (in equity) per company through subsequent rounds of investment. The firm seeks to invest in companies that are based in the US and Europe. The firm is actively seeking new investment opportunities.

In the life sciences, the firm seeks to invest in medical devices and digital health. The firm is opportunistic in terms of subsectors and indications. Medical devices with a therapeutic focus are of high interest. The firm seeks growth stage companies with early sales or with products that, at minimum, have regulatory approval (CE mark) and compelling clinical data.

The firm requests a board seat in each portfolio company and generally holds a significant minority stake. The firm seeks a company with a strong management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A UAE registered investment consultancy firm’s core activities involve independent advisory, outsourced CIO, and direct investments. The firm acts as the consultant role to advise global family offices with their investment objectives. The firm looking for investment leads in early-stage life science industry. Companies who are looking to raise their series B – series C rounds would be the sweet spot. The firm typically invests in $5M-25M, which depends on the stage of development. The firm is also open to looking at earlier stage companies but the investment size might vary. The firm is looking for companies in the US (60%), China (20%), UK, Germany, India, and other countries with emerging life science technologies.

The firm is opportunistic in sectors and is willing to consider any indications.

The firm has no specific requirements for companies. The firm might take an observer seat or board seat in applicable cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 2016 with offices in USA and China invests exclusively in healthcare companies (therapeutics, medical devices, digital health, and healthcare services). The firm typically invests $1-5M (USD) of equity capital with the ability to make follow-on investment. The fund aims to make at least 5 investments per year, but this is not a fixed number. In general, the firm participates in seed, series A and series B funding rounds. The firm looks at companies of all parts of the world and has a strong preference for companies that have market opportunities in the US, Europe and China. The firm’s China office can provide companies with the resources they need for successful market entry in Asian markets.

The firm looks at all sectors pertaining to healthcare, including biotech therapeutics, R&D services, diagnostics, medical devices, and digital health. While the firm’s focus is in early-stage companies, it takes a very opportunistic viewpoint. In therapeutics, the firm will look at products of all stages from pre-clinical to phase III, and is open to all indications. In terms of medical devices, the firm will consider both 510k and PMA devices. In addition, the firm will also consider products that are already on the market.

The firm is open to both public and private companies, and expects them to have an experienced management team with a strong exit strategy. The firm requires a board seat in all portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm headquartered in Japan manages a fund dedicated specifically to life science investments. Though it could largely vary on a deal-by-deal basis, the firm’s initial size of investment is usually around $1M, with a significant portion dedicated to follow-on investments. Geographically, the firm is focused on companies headquartered in Japan and those that are looking to expand into the Japanese market.

The firm is most interested in biotech and digital health technologies. The firm is very interested in emerging therapeutic technologies such as cell and gene therapy, as well as platform technologies. With regards to digital health technologies, the firm is most interested in (i) IT solutions for people in terms of health management, disease prevention, diagnosis, therapy, disease management, and nursing care; (ii) healthcare industry in terms of drug discovery & development, medical information, distribution system by leveraging AI, big data, IoT, VR, etc. The firm is opportunistic in terms of stage, and will seek opportunities that are pre-clinical and beyond.

The firm is actively seeking opportunities in Japan and those that are looking to expand into Japan. The firm will prefer to lead investments in companies headquartered in Japan where they can best leverage their resources and network, but will generally follow larger syndicates for deals outside of Japan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the USA is interested in a broad range of technology companies, including those in the software, cloud services, IT, and Internet sectors. In the life sciences, the firm will only invest in the healthcare IT sector. The firm invests in late seed to early Series A rounds with a typical investment size ranges from $50,000 to $2M. Investment is typically in form of equity, though convertible loan and other capital structures would be considered as well. The firm will look at investment opportunities across the US with a focus on West Coast.

The firm will make new investments in the healthcare IT sector. The firm is interested in healthcare services and IT companies targeting platform, enterprise software, m-health, solution, data analytics and consumer health. The firm will invest in commercial-stage companies with products or services on the market.

The firm invests in privately held healthcare companies. The firm focuses on companies with annual revenues of between $0.5M and $10M.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A high-tech enterprise headquartered in China focuses on the R&D, manufacturing and sales of implantable medical devices. The firm is actively seeking external opportunities for investment and other types of strategic partnerships. With regards to investment, the firm will generally invest several millions of dollars per deal. The firm is open to global opportunities.

The firm is interested in expanding their business by investing and partnering with medical device companies. The firm is not interested in therapeutics, diagnostics, or digital health. The firm is most interested in Class III implantable medical devices, but will not exclude Class I or II. The firm is open to working with companies across all stages of development.

The firm has 2 main focuses within medical devices, according their stage of development:

(1) Products at early development stage: The firm is open to investing in companies at the idea-level, or those with a prototype that have not yet started clinical trials. In addition to direct equity investment in these stages, the firm is also interested in accelerating the path to market by helping with product development, regulatory and preclinical tests. The firm can act as a lead or co-investor.

(2) Products at later stage: For products that have demonstrated efficacy through clinical trials with patients, the firm is open to exploring beyond direct investment, such as joint venture, licensing, co-development, etc. The firm can provide strategic value to these companies and also assist with China market entry.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An active life sciences accelerator that funds, supports and advances life science technologies from early development through clinical proof-of-concept recently established a joint venture fund to support early-stage innovation. The firm’s experienced leadership team works with scientists and entrepreneurs to provide active mentorship, financing solutions and operational guidance to increase the probability of success in early drug development. The firm has access to capital to support companies from seed investment through Series A and B financings through the firm’s internal resources and the joint venture fund.

The size of initial seed investment can range from $0.5M to $1.5M. The subsequent Series A investments will be sized to get through preclinical and IND-enabling work and/or through a clinical development study and can range between $8M-$20M, with flexibility to syndicate with investors for larger rounds. For more mature companies that don’t require a seed round or the need to do complete activities/studies prior to a Series A, the fund can invest directly as a Series A investment along with participation in related Series B investments.  Lastly, this new fund is part of the accelerator’s partner’s umbrella of funds, which can support companies in later-stage private/mezzanine/crossover financings, debt financings, and IPO/follow-on public offerings. The firm is open to global opportunities.

The firm and the newly established fund support opportunities across all therapeutic areas and drug modalities (small molecule, peptides, antibodies, genetic technologies, cell therapy, etc.).  Additionally, open to technologies beyond drug therapeutics, including medical devices, diagnostics and emerging healthtech opportunities (digital health, telemedicine, enabling technologies utilizing AI/ML, etc.). Founder and entrepreneur friendly, supportive of first-time CEOs, and works side by side to drive value inflections with the goal to optimize program development and successful outcomes.

The firm is open to working with all types of management teams, including first time entrepreneurs. The firm works hands-on with its portfolio companies by bringing a powerful network, access to resources and expertise to support their growth. The firm prefers to lead but is open to participating with likeminded co-investors to form syndicates.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.